Bracing for the biosimilar wave.
作者信息
Mullard Asher
出版信息
Nat Rev Drug Discov. 2017 Mar 1;16(3):152-154. doi: 10.1038/nrd.2017.36.
PMID:28248938
Abstract
摘要
相似文献
1
Bracing for the biosimilar wave.为生物类似药浪潮做好准备。
Nat Rev Drug Discov. 2017 Mar 1;16(3):152-154. doi: 10.1038/nrd.2017.36.
2
Regulatory watch: Innovation in biologic new molecular entities: 1986-2014.监管观察：生物新分子实体的创新：1986 - 2014年
Nat Rev Drug Discov. 2015 Feb;14(2):83. doi: 10.1038/nrd4535.
3
Patent watch: Have the biosimilar floodgates been opened in the United States?专利观察：美国的生物类似药闸门是否已经打开？
Nat Rev Drug Discov. 2015 May;14(5):303-4. doi: 10.1038/nrd4622.
4
Assessing biosimilarity and interchangeability of biosimilar products.评估生物类似药产品的生物相似性和可互换性。
Stat Med. 2013 Feb 10;32(3):361-3. doi: 10.1002/sim.5577.
5
Pediatric Exclusivity and Regulatory Authority: Implications of Amgen v HHS.儿科专属权与监管机构：安进公司诉美国卫生与公众服务部案的影响
JAMA. 2018 Jan 2;319(1):21-22. doi: 10.1001/jama.2017.16477.
6
First biosimilar drug approved for sale in the United States.首款生物类似药获美国批准上市。
J Natl Cancer Inst. 2015 Jul 3;107(7). doi: 10.1093/jnci/djv191. Print 2015 Jul.
7
A cheat sheet to navigate the complex maze of exclusivities in the United States.一份用于在美国错综复杂的专有权益迷宫中导航的备忘单。
Pharm Pat Anal. 2014 Jul;3(4):339-43. doi: 10.4155/ppa.14.30.
8
Considerations in the early development of biosimilar products.生物类似药产品早期开发中的考量因素。
Drug Discov Today. 2015 May;20 Suppl 2:1-9. doi: 10.1016/j.drudis.2014.12.017. Epub 2015 Jan 6.
9
Biosimilars: where we were and where we are.生物类似药：我们的过去与现在。
J Biopharm Stat. 2014;24(6):1154-64. doi: 10.1080/10543406.2014.941994.
10
Biosimilars in the Caribbean--key considerations.加勒比地区的生物类似药——关键考量因素
West Indian Med J. 2012 Dec;61(9):849-52. doi: 10.7727/wimj.2012.331.
引用本文的文献
1
Rituximab for the treatment of multiple sclerosis: a review.利妥昔单抗治疗多发性硬化症：综述
J Neurol. 2022 Jan;269(1):159-183. doi: 10.1007/s00415-020-10362-z. Epub 2021 Jan 8.
2
Antiproliferative Effects of Alkaloid Evodiamine and Its Derivatives.生物碱吴茱萸碱及其衍生物的抗增殖作用。
Int J Mol Sci. 2018 Oct 30;19(11):3403. doi: 10.3390/ijms19113403.
3
Barriers to Oncology Biosimilars Uptake in the United States.美国肿瘤生物类似药采用的障碍。
Oncologist. 2018 Nov;23(11):1261-1265. doi: 10.1634/theoncologist.2018-0066. Epub 2018 Jul 26.
4
Bracing for the biosimilar wave.为生物类似药浪潮做好准备。
Nat Rev Drug Discov. 2017 May;16(5):367. doi: 10.1038/nrd.2017.64. Epub 2017 Mar 31.
Zotero 插件